Long‑term effect of panitumumab therapy in a patient with primarily generalized colorectal cancer – case report


MUDr. Anna Nohejlová Medková

Onkologická klinika 2. LF UK a FN v Motole, Praha



Colorectal cancer is one of the most common tumors in the Czech Republic. For metastatic patients with the wild type RAS gene, the therapy with monoclonal antibodies targeting epidermal growth factor receptor (EGFR) is available. Most patients develop skin toxicity with this therapy, which has a major impact on their quality of life; so prevention of side effects and testing of RAS genes leads to an improved management of patients with metastatic colorectal cancer. I describe a case of a patient who underwent the therapy with panitumumab and his multiple liver metastases have disappeared.


Key words

colorectal cancer, anti EGFR therapy, panitumumab, RAS mutation



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...